Prevalence of D variants in the Indian donor population

Subramaniyan, Rajeswari

doi:10.1016/j.htct.2018.09.004

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Various genetic studies classify D antigen into Weak D, Partial D, Weak Partial D and Del. 16 Weak D: This is due to substitution of amino acid in transmembrane or intracellular segment of Rh D protein. This substitution leads to decrease expression of D antigen i.e.…”

Section: Discussionmentioning

confidence: 99%

Prevalance of serologic weak D in Rh D negative blood donors in India: Immunohematological problems & recommendations for donors

Chandra¹,

Singh

Solanki³

et al. 2022

PJMS

View full text Add to dashboard Cite

The Rhesus (Rh) system is one of the most complex blood group systems in humans. In some individuals Rh D antigen show weaker expression on red cells. The aim of the study was to find out the prevalence of serologic weak D in north India and associated immunohematological problems.Cell and serum grouping were performed on all sample with the help of Qwalys 2 & Qwalys 3 (Diagast, France). All Rh D negatives samples in routine blood grouping were subjected to serologic weak D testing with the help of Erythrocytes Magnetized (EM) Technology.Total 65,407 whole blood donors were tested for blood grouping in the study period. Prevalence of serologic weak D phenotype in this study was 1.11% of Rh negative donors. The maximum number of serologic weak D phenotype were from B blood group, i.e. 13 (37.14%). The prevalence of serologic weak D varies in different part of India as well as in the world. This study reported 1.11% prevalence of serologic weak D among Rh D negative blood donors. All serologic weak D positive individuals should give a blood group card showing their Rh D status as donor and recipient. Some European centers started routine RHD gene screening of first-time donors to eliminate the risk of Rh D sensitization. Molecular testing is very costly.For developing countries like India we required an affordable molecular testing technique to improve patient care or alternatively establish reference molecular laboratory for cost effectiveness.

show abstract

Section: Discussionmentioning

confidence: 99%